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Intestinal epithelial cells (IECs) play a key role in regulating
immune responses and controlling infection. However, the direct
role of IECs in restricting pathogens remains incompletely un-
derstood. Here, we provide evidence that IL-22 primed intestinal
organoids derived from healthy human induced pluripotent stem
cells (hIPSCs) to restrict Salmonella enterica serovar Typhimurium
SL1344 infection. A combination of transcriptomics, bacterial inva-
sion assays, and imaging suggests that IL-22–induced antimicrobial
activity is driven by increased phagolysosomal fusion in IL-22–
pretreated cells. The antimicrobial phenotype was absent in hIPSCs
derived from a patient harboring a homozygous mutation in the
IL10RB gene that inactivates the IL-22 receptor but was restored by
genetically complementing the IL10RB deficiency. This study high-
lights a mechanism through which the IL-22 pathway facilitates
the human intestinal epithelium to control microbial infection.
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Recent advances in stem cell biology have enabled the pro-duction of human induced pluripotent stem cells (hIPSCs)
from different donors to become more routine (1, 2). hIPSCs can
be generated from healthy individuals or from patients harboring
mutations of clinical interest, facilitating studies on phenotypic–
genotypic associations (3, 4). Inflammatory bowel disease (IBD)
can develop in infants due to, among other causes, loss-of-
function mutations in IL10, IL10RA, and IL10RB (5, 6). In ad-
dition to IBD with severe perianal disease, patients with IL-10–
signaling defects develop chronic folliculitis and arthritis (7). The
development of IBD involves complex interactions between host
genetics that impact intestinal barrier function and intestinal
immunity, the environment, and the intestinal microbiota (8).
IL10R2 encoded by the IL10RB gene is a component of the
heterodimeric IL-10 receptor (IL10R) as well as a component of
the receptor for IL-22 (IL22R). Due to the common IL10R2
receptor chain that can pair with several R1 subunits, patients
with loss-of-function mutations in IL10RB are nonresponsive to
the cytokines IL-10, IL-22, IL-26, IL-28A, IL-28B, and IL-29 (5).
IL10R2 is expressed constitutively across many cell types in the
body, whereas IL22R1 is expressed mainly on nonhematopoietic
cells lining barrier sites, including the intestine (9–11). A key role
for IL-22 is maintenance of the gastrointestinal barrier. Mice
deficient in IL-22 or the IL-22 receptor Il22ra1 can be suscep-
tible to severe disseminated bacterial infection after chemically
induced colitis or Citrobacter rodentium challenge (12, 13).
Intestinal organoids are beginning to provide a reductionist
system to dissect the cell-intrinsic role of intestinal epithelial cells
(IECs) in host defense. Murine intestinal organoids exposed to IL-
22 displayed evidence of an inflammatory response, enhanced
antimicrobial activity, and wound healing (12). Here, we explore
the role of IL-22 in priming IEC responses to the enteric pathogen
Salmonella enterica serovar Typhimurium, using hIPSC-derived
intestinal organoids (iHOs), including those generated from a
patient with infantile IBD due to an IL10RB defect, as a model
system. Our results provide insights into an IL-22–driven bacterial
defense mechanism involving enhanced phagolysosomal fusion.
Results
iHOs Derived from a Patient with Infantile IBD Lack Expression of
IL10RB. To explore whether iHOs provide a suitable system to study
the IL-22 pathway, the expression patterns of mRNAs encoding
IL22R1 and IL10R2, the receptor subunits for IL-22, were
examined in iHOs derived from hIPSCs using our established
protocol (Fig. 1) (14). iHOs were differentiated from the in-
dependently derived hIPSC lines Yemz1, Lise1, and Kolf2 as
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well as from hIPSCs derived from an individual with infantile IBD
who harbored a homozygous splice site mutation at the boundary
between intron and exon 3 in the IL10RB gene (hereafter
“IL10RBPat”) (7). Six weeks after the generation of iHOs from
each hIPSC line, the resulting iHOs were phenotyped for ex-
pression of markers of mature intestinal epithelium (Fig. 1 and SI
Appendix, Fig. S1). mRNA was detected for IL22RA and IL10RB
in iHOs from all lines, but significantly lower mRNA levels of
IL10RB were detected in the IL10RBPat iHOs than in healthy
control iHO lines (Fig. 1A). However, in contrast to mapped
RNA-sequencing (RNA-seq) reads from Kolf2 iHOs, no reads
mapped to exon 3 in the corresponding IL10RBPat iHO samples
(SI Appendix, Fig. S2A). To generate a complemented isogenic
control line for IL10RBPat (hereafter “IL10RBComp”), TALEN-
based engineering was used to introduce a functional IL10RB
gene into the adeno-associated virus site 1 (AAVS1 site) in the
IL10RBPat genome (15, 16). After transfection and 7-d puromycin
selection, RT-qPCR was performed on surviving colonies with
IL10RB-specific primers to detect mRNA expression. One clone
was selected for differentiation; the quantity and morphology of
hIPSC colonies for this clone were indistinguishable from control
hIPSCs. RNA was prepared from differentiated IL10RBPat and
IL10RBComp iHOs, which displayed phenotypes similar to healthy
control iHOs in culture (SI Appendix, Fig. S3), and from their
hIPSC progenitors, and levels of IL10RB mRNA were assayed by
RT-qPCR (Fig. 1B). IL10RB gene expression was significantly
higher in IL10RBComp iHOs than in IL10RBPat iHOs. At the
protein level, IL22R1 and IL10R2 expression was observed on the
basal surface of Kolf2 iHOs but not IL10RBPat iHOs using
immunostaining (Fig. 1C). The IL22R1 protein was clearly visible
dispersed across the basal surface of the iHO epithelia. In con-
trast, the IL10R2 protein was more obvious as clusters associated
with individual cells, often colocalizing with markers for enter-
oendocrine cells, a feature observed in both iHOs (SI Appendix,
Fig. S2C) and primary intestinal tissue (SI Appendix, Fig. S4). As
expression of receptors was basal, in subsequent assays IL-22 was
delivered to the basal surface of iHOs. Although expression of
IL10RB was consistent in healthy control hIPSC lines (Fig. 1A),
IL10RB expression was routinely higher in IL10RBComp hIPSCs,
probably due to the use of a different promoter (Fig. 1B). How-
ever, expression of IL10R2 protein was detected in IL10R2Comp
iHOs at comparable levels to expression in Kolf2 iHOs (Fig. 1C).
In control human ileal and colonic tissue similar patterns of
marker staining were observed to iHOs (SI Appendix, Fig. S4).
To confirm the lack of surface expression of IL10R2 in
IL10RBPat iHOs, flow cytometry was performed. In Kolf2 iHOs
6% of IECs were positive for IL10R2 expression, confirming
the diffuse expression observed via immunostaining, whereas
IL10RBPat iHOs were entirely negative (SI Appendix, Fig. S2B).
IL10R2 Is Necessary for iHO Responses to IL-22. To probe for tran-
scriptional changes in IL-22–prestimulated iHOs, a global tran-
scriptomic analysis was performed in Kolf2 iHOs that were left
untreated or were treated with IL-22 for 18 h (SI Appendix, Fig.
S5 A and B). Principal component analysis (SI Appendix, Fig.
S5A) showed that iHOs treated with IL-22 and untreated iHOs
formed distinct groups. A heatmap for the 30 most highly up-
regulated IL-22–responsive genes (SI Appendix, Fig. S5B and
Datasets S1 and S2) included the antimicrobial proteins REGIIIα
and REGIβ and the mucin-encoding gene MUC1, which are
potentially expressed by Paneth and goblet cells, respectively.
Several IFN-regulated genes associated with antiviral and anti-
mycobacterial defenses, including IFITM1, IFITM2, and IFITM3,
were relatively up-regulated (17). Components involved in the
maturation and processing of the epithelial oxidase complex
DUOX2, DUOXA2, and DUOXA1 were also up-regulated (18),
along with DMBT1, which can restrict Salmonella entry into
cultured IECs (19). When treated with IL-22 for 18 h, Yemz1,
Lise1, and Kolf2 iHOs significantly up-regulated DUOX2 and
LCN2 mRNA (Fig. 2A), previously demonstrated to be regu-
lated by IL-22 in other model systems (12, 20). Levels of
DUOX2 and LCN2 mRNA did not change significantly in
IL10RBPat iHOs after IL-22 treatment; however, the IL-22
response was restored in IL10RBComp iHOs (Fig. 2A). At ear-
lier time points of 3 and 6 h we did not observe up-regulation of
DUOX2 and LCN2 (SI Appendix, Fig. S5D). STAT3 activation
was detected by Western blotting in whole-cell lysates from healthy
controls (Kolf2 and Yemz1 iHOs) and IL10RBComp iHOs but not
the IL10RBPat iHOs after 30-min treatment with IL-22 (Fig. 2B).
To visualize changes in the barrier phenotype of iHOs treated with
IL-22, we performed immunostaining with antibodies for Mucin 4
after IL-22 treatment (Fig. 2C), showing enhanced Mucin 4 pro-
duction. Mucin 4 production was also enhanced in IL10RBComp
iHOs but not in IL10RBPat iHOs (Fig. 2D). We have shown here
that, after IL-22 treatment, iHOs up-regulated various antimicrobials
and components of the intestinal barrier defense. Hence, we per-
formed RNA-seq and subsequent gene-expression analyses for
mRNA in Kolf2 iHOs treated with IL-22 alone or with S. enterica
Typhimurium SL1344 added to the medium for 3 h. S. enterica
Typhimurium exacerbated the expression of numerous genes in iHOs
(SI Appendix, Fig. S5C and Datasets S3 and S4), which was con-
firmed using RT-qPCR for LCN2, DUOX2, and CXCL2 (SI Ap-
pendix, Fig. S5E). Therefore, we hypothesized that during infection
IL-22–pretreated iHOs might be less susceptible to invasion by S.
enterica Typhimurium SL1344 due to the induction of barrier and
host defense mechanisms by IL-22 treatment.
IL-22 Induces a Protective Phenotype Against S. enterica Serovar
Typhimurium Infection in iHOs. To establish whether IL-22 had an
effect on the early interaction of S. enterica Typhimurium with
iHOs, we pretreated iHOs with IL-22 for 18 h and then performed
Fig. 1. Analysis of expression of IL-22R subunits IL22R1 and IL10R2 dem-
onstrated that iHOs generated from healthy control hIPSCs express the re-
ceptors for IL-22, IL22R1, and IL10R2, in contrast to iHOs generated from a
patient with infantile IBD, which lack the IL10R2 subunit. To generate
IL10RBComp, an isogenic control line for patient iPSCs (IL10RBPat), TALEN-
mediated gene integration was used to integrate a copy of the IL10RB
gene into the AAVS1 site in IL10RBPat iPSCs. (A) mRNA levels determined by
RT-qPCR for IL22RA and IL10RB in three healthy control iHO lines (Yemz1,
Lise1, and Kolf2), IL10RBPat iHOs, and control duodenal tissue. IL10RB is sig-
nificantly up-regulated in control iHOs in comparison with IL10RBPat (P =
0.0005, P < 0.0001, and P < 0.0001, respectively; Student’s t tests). (B) RT-qPCR
analysis shows significant up-regulation of IL10RB expression in IL10RBComp
iHOs in comparison with IL10RBPat iHOs (P < 0.0001; unpaired, two-tailed
Student’s t test). RT-qPCR was performed with TaqMan gene-expression as-
says and analyzed via the comparative cycle threshold (CT) method with
GAPDH as an endogenous control. Data are presented from four technical
replicates, with assays repeated at least three times from independent iHO
batches. **P < 0.001; ***P < 0.0001. (C) Z-stacked immunostaining for IL-22
receptors IL10R2 or IL22R1 (green) and DAPI (blue) on healthy control Kolf2,
IL10RBComp, and IL10RBPat iHOs showing localization of IL22R1 and IL10R2 on
the basal IEC surface, with IL10R2 not detected in IL10RBPat iHOs. (Original
magnification: 20×.)
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microinjections with S. enterica Typhimurium SL1344 (Fig. 3).
Interestingly, modified gentamicin protection assays measuring
bacterial intracellular survival demonstrated that in Kolf2 and
IL10RBComp iHOs significantly less S. enterica Typhimurium was
recovered from IL-22–pretreated iHOs than from untreated iHOs,
in contrast to IL10RBPat iHOs, in which no significant difference was
observed between pretreated and untreated iHOs (Fig. 3A). We then
performed similar assays in Kolf2, IL10RBComp, and IL10RBPat
iHOs using a fluorescently tagged S. enterica Typhimurium SL1344
(TIMERbac-Salmonella) (Fig. 3B), which can yield bright fluores-
cence in the green/orange channel, depending on replication state
(21). The percentage differences in Salmonella counts between un-
treated and IL-22–pretreated iHOs in the IL10RBPat samples were
significantly lower than the corresponding differences between un-
treated and IL-22–pretreated iHOs in the Kolf2 and IL10RBComp
iHOs. These protection assays were designed to measure differences
in levels of intracellular bacteria. In addition, we performed luminal
killing assays using S. enterica Typhimurium SL1344 and an S.
Typhimurium SL1344 invAmutant, which we have previously shown
to be ∼30 times less invasive in the iHO system (Fig. 3C) (14). In
these assays bacteria were harvested directly from the iHO luminal
cavity. There was no significant difference in the counts recovered
from untreated or IL-22–pretreated iHOs, suggesting that luminal
killing did not explain the phenotypic differences observed in the in-
vasion assays. We also measured initial invasion by performing pro-
tection assays with intracellular bacteria harvested after 30 min (Fig.
3E). Here, we saw a significant reduction in intracellular S. enterica
Typhimurium counts in Kolf2 iHOs prestimulated with IL-22, sug-
gesting that the initial invasion was inhibited by IL-22. However, as-
says were also performed to assess longer-term intracellular survival
by incubating infected iHOs for a further 90 min post infection (Fig.
3E). Here, a greater difference was observed in bacterial counts re-
covered from IL-22–pretreated iHOs compared with untreated iHOs.
IL-22 Induces a Protective Phenotype in Primary Mouse and Human
Organoids. To ensure that IL-22–mediated restriction was not an
artifact of the iHO system, we repeated gentamicin protection
Fig. 2. Expression of IL10RBwas required for iHO responses to IL-22. iHOs were
treated with 100 ng/mL recombinant human IL-22 (rhIL-22) added to the iHO
medium. (A) In iHO lines with a functional copy of IL10RB, transcripts for IL-22–
regulated genes lipocalin 2 (LCN2) and dual oxidase 2 (DUOX2) are significantly
up-regulated after the addition of 100 ng/mL rhIL-22 for 18 h, in comparison
with unstimulated iHOs (**P < 0.001; ***P < 0.0001; unpaired, two-tailed,
Student’s t tests; n.s., not significant). Data are presented from four technical
replicates; assays were repeated with at least three biological replicates. RT-qPCR
was performed with TaqMan gene-expression assays and analyzed via the
comparative CT method with GAPDH as an endogenous control. (B) Phospho-
STAT3 level was detected by Western blot after stimulation of healthy control
(Yemz1 and Kolf2), IL10RBPat, and IL10RBComp iHOs for 30 min with rhIL-22 and
preparation of whole-cell extracts. To verify equal protein loading, the blot
was stripped and reprobed with STAT3 antibody. Lysate from HeLa cells
stimulated with IFNλ were used as a positive control. (C) Kolf2 iHOs challenged
with IL-22 for 18 h or left untreated were examined for Mucin 4 (MUC4; green)
and DAPI (blue) by immunofluorescence. (D) Z-stacked immunostaining for
Mucin 4 in IL10RBPat and IL10RBComp iHOs challenged with IL-22 for 18 h or
were left untreated. (Original magnification: 20×; L = iHO lumen.)
Fig. 3. Pretreatment with rhIL-22 of iHOs that express both IL22R1 and
IL10R2 restricts S. enterica Typhimurium SL1344 invasion into IECs. For pro-
tection assays iHOs were treated with 100 ng/mL IL-22 18 h before infection
or were left untreated. After injection of S. enterica Typhimurium SL1344
into the luminal cavity, iHOs were incubated for 90 min unless otherwise
stated. Bacteria were recovered either from the luminal cavity or from IECs.
The data presented show the mean from three technical replicates from the
combined total of 25 iHOs per replicate, ± SEM, unless otherwise stated. For
significance testing unpaired, two-tailed, Mann–Whitney U tests were used
for all assays. *P < 0.05; **P < 0.001; ***P < 0.0001; n.s., not significant. (A)
Gentamicin protection assays in iHOs show that pretreatment with IL-22
results in significantly less invasion after microinjection of S. enterica
Typhimurium SL1344 in healthy control lines with functional IL10R2 (Kolf2:
P = 0.0012; IL10R2Comp: P < 0.0001), but this phenotype is not observed in
IL10RBPat iHOs (P = 0.2). (B) Percentage difference in TIMERbac Salmonella-
infected cells assayed by flow cytometry recovered from untreated or IL-22–
treated iHOs (40 iHOs per condition), with gating on live cells. There were sig-
nificant differences between Kolf2 samples (P = 0.0214) or IL10RBComp samples
and IL10RBPat samples (P = 0.0002; Kruskal–Wallis test with Dunn’s multiple
comparison test). (C) Log numbers of cfu/mL recovered from lumens of iHOs
after microinjection of untreated or IL-22–pretreated Kolf2 iHOs with SL1344 or
an invasion-deficient strain, S. enterica Typhimurium SL1344 invA. There was no
significant difference in numbers recovered. (D) Protection against S. enterica
Typhimurium infection after IL-22 pretreatment is observed in human primary
duodenal organoids. Data presented show the mean from three biological
replicates with 10 organoids injected per replicate, ± SEM (P < 0.0001).
(E) Modified gentamicin protection assays in Kolf2 iHOs show that pretreatment
with IL-22 results in significantly less initial invasion (30-min incubation) after
microinjection of S. enterica Typhimurium SL1344 (P < 0.0001) and also signifi-
cantly less intracellular survival, when infected iHO IECs were incubated for an
additional 90 min after gentamicin treatment and before IEC lysis (P < 0.0001).
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assays in primary organoid systems (Fig. 3D and SI Appendix, Fig.
S6C). In primary human duodenal organoids pretreated with IL-
22 we recovered significantly fewer cfu/mL in protection assays
(Fig. 3D) and confirmed the up-regulation of IL-22–responsive
genes assayed by RT-qPCR (SI Appendix, Fig. S6 A and B).To
confirm that IL-22–mediated protection was driven by signaling
via IL22R1, murine intestinal organoids (iMOs) were generated
from mucosal tissue harvested from wild-type and Il22ra1−/−mice,
and protection assays were performed (SI Appendix, Fig. S6C). In
iMOs derived from Il22ra1−/− mice there was no significant dif-
ference in the bacterial numbers recovered upon IL-22 treatment.
The Protective Phenotype Induced by IL-22 Pretreatment of iHOs Is
Driven by Enhanced Phagolysosomal Fusion. Our protection assays
demonstrated that intracellular survival in IL-22–pretreated iHOs
was significantly reduced, suggesting differences in the intracellular
environment after induction of IL-22 signaling (Fig. 3). Therefore,
transmission electron microscopy (TEM) was used to image in-
tracellular bacterial populations at high resolution (Fig. 4 and SI
Appendix, Fig. S7 A and B). Interestingly, a distinct difference in
bacterial populations was observed within IL-22–treated compared
with untreated iHOs. In IL-22–pretreated iHOs, bacteria were
visibly more degraded based on the scoring system presented in SI
Appendix, Fig. S7B. Histopathological scores from 100-μM sections
of 1 mm of iHO mucosa demonstrated that there were more de-
graded bacteria in Kolf2 iHOs pretreated with IL-22 than in un-
treated iHOs (49 in pretreated iHOs vs. 11 in untreated iHOs).
Moreover, more phagolysosomes were observed in IL-22–
pretreated iHOs. To test this observation quantitatively, we used
blinded scoring and collected counts for bacterial localization
according to the feature scoring system presented in SI Appendix,
Fig. S7A. In IL-22–responsive iHOs, the proportion of phag-
olysosomes to total Salmonella-containing vacuoles (SCVs) was
significantly higher in iHOs pretreated with IL-22 before infection
than in untreated iHOs (SI Appendix, Table S1). In IL10RBPat
iHOs this phenotype was lost. IL-22 can restrict the growth of
Mycobacterium tuberculosis intracellularly in macrophages by en-
hancing phagolysosomal fusion (22) and could be blocked by
treatment with the phagolysosomal fusion inhibitor W7. W7 is a
specific inhibitor of Ca2+/calmodulin interactions with binding
partners, which have been shown to be part of a signaling pathway
necessary for converting phagosomes into phagolysosomes (23).
We added W7 for 6 h to iHOs pretreated with IL-22 for 18 h
before infection with S. enterica Typhimurium SL1344. This
revealed that, in the presence of W7, intracellular bacterial counts
recovered were similar to those recovered from untreated iHOs
(Fig. 5A). This phenotype was then replicated using concanamycin
A, a vacuolar ATPase inhibitor that is also known to inhibit
phagolysosomal fusion and acidification of phagosomes (Fig. 5A)
(24, 25). To confirm that W7 and concanamycin A were not
impacting bacterial invasion by restricting any other pathways, in-
vasion assays with S. enterica Typhimurium in Kolf2 iHOs were
repeated, and iHOs were treated with either W7 or concanamycin
A (SI Appendix, Fig. S7C) or were left untreated; no significant
difference in recovered intracellular bacteria was observed. W7 and
CCMA assays were repeated in IL10RBPat and IL10RBComp iHOs,
demonstrating that in IL10RBComp blocking of phagolysosomal
fusion with W7 also inhibited IL-22–mediated intracellular S.
enterica Typhimurium restriction (SI Appendix, Fig. S7E). It is well
established that the Rab family GTPase RAB7 marks late endo-
somes and late phagosomes (26). Therefore, we performed RT-
qPCR and immunostaining of infected iHOs with RAB7-specific
primers or antibodies. In Kolf2 iHOs a significant difference in
fold change of RAB7A was observed between iHOs pretreated with
IL-22 and those left untreated before infection (Fig. 5B). We also
observed strong RAB7 staining in S. enterica Typhimurium-infected
iHOs pretreated with IL-22, with visible colocalization between
CSA-1, which stains Salmonella, and RAB7 (Fig. 5D). This pheno-
type was lost in IL10RBPat iHOs and was restored in IL10RBComp
iHOs (SI Appendix, Fig. S7D). In addition, less RAB7 expression via
immunostaining was observed in iHOs in which W7 was added
before microinjection of S. enterica Typhimurium SL1344 (Fig.
5D, Bottom).
Calgranulin B Enhances IL-22–Induced Phagolysosomal Fusion. Ob-
servations by Dhiman et al. (27) suggested that increased expres-
sion of calgranulin A (S100A8) was essential for IL-22–dependent
mycobacterial growth inhibition through enhancement of phag-
olysosomal fusion. No differential expression of S100A8 was ob-
served in our RNA-seq experiments; however, increased expression
of calgranulin B (S100A9) was observed after exposure of iHOs
to IL-22 and S. enterica Typhimurium (Dataset S3), and was
confirmed via RT-qPCR (Fig. 5C) and immunostaining (SI
Appendix, Fig. S7G). S100A9 is induced by IL-6 signaling in co-
lonic cells via the interaction of activated STAT3 with the S100A9
promoter (28). Therefore, we reasoned that the IL-22 pathway
might be triggering similar induction of S100A9 through STAT3
activation and thus decided to assess the role of S100A9 in IL-22–
mediated phagolysosomal fusion. To this end, a biallelic mutation in
S100A9 was generated in Kolf2 hIPSCs using CRISPR/Cas9 engi-
neering. In iHOs derived from S100A9−/− hIPSCs, which were
morphologically similar to other iHO lines (SI Appendix, Fig.
S3), no expression of S100A9 protein via immunostaining was
detected after stimulation with IL-22 and S. enterica Typhimu-
rium SL1344 (Fig. 5E). Gentamicin protection assays in
S100A9−/− iHOs demonstrated no significant difference in in-
tracellular S. enterica Typhimurium recovered from IL-22–
pretreated iHOs in comparison with untreated iHOs (Fig. 5F),
suggesting that IL-22–induced S100A9 directly inhibits S. enterica
Typhimurium colonization. To ensure that this phenotype was
not due to lack of IL-22 response in S100A9−/− iHOs, mRNA
levels of the IL-22–regulated genes LCN2 and DUOX2 were
assessed after IL-22 treatment, revealing significant increases in
the expression of both genes (SI Appendix, Fig. S7F). We then
performed immunostaining for RAB7 in Kolf2 or S100A9−/−
Fig. 4. IL-22 protection was mediated through enhanced lysosomal fusion
with SCVs in IL-22–treated iHOs. TEM images of S. enterica Typhimurium
SL1344 internalized into IECs 90 min after injection into the lumen of Kolf2
iHOs pretreated for 18 h with 100 ng/mL IL-22 (Lower) or left untreated
(Upper), showing healthy bacteria in untreated organoids and degraded
bacteria, often associated with lysosomes, in IL-22–pretreated iHOs. Repre-
sentative images for each treatment condition were selected from 30 iHOs
injected and processed per condition. Numbers indicate characterizations of
bacterial cell damage/stress used for scoring: widening of periplasmic space
(1); membrane damage and ragged appearance (2); decrease in cytosol den-
sity (3); direct contact with lysosomes (4); and presence of volutin granules (5).
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iHOs treated with IL-22 and infected with S. enterica Typhi-
murium (Fig. 5G), observing a lack of RAB7 in S100A9−/−
iHOs.
Discussion
We have shown that iHOs generated from healthy control hIPSCs
expressed IL-22 receptors on their basal surface and were re-
sponsive to IL-22. Conversely, IL-22 response was lost in iHOs
generated from a patient with a loss-of-function mutation in
IL10RB. Pretreatment of responsive iHOs with IL-22 appeared to
drive a “barrier phenotype” as IL-22–primed iHOs were less sus-
ceptible to colonization by S. enterica Typhimurium, and prolonged
incubation enhanced differences in bacterial survival. Through
detailed imaging studies we attributed the IL-22–dependent pro-
tective phenotype to increased intracellular fusion of SCVs with
lysosomes. Since fusion with the lysosome ends in degradation,
some pathogens that enter the cell through the endocytic or
phagocytic pathway are adapted to avoid this fusion (29). S. enterica
Typhimurium has been shown to be capable of avoiding phag-
olysosomal fusion by modulating networks of Rab proteins that are
recruited to the phagosome (30). To our knowledge, there have
been no published reports showing that IL-22 prompts increased
lysosomal fusion as a mechanism for restricting S. enterica
Typhimurium growth in IECs. IL-22 can restrict the growth of M.
tuberculosis intracellularly in macrophages by enhancing phagosomal
fusion (22), and calgranulin A (S100A8) is required for this pro-
cess (27). In iHOs we found that calgranulin B (S100A9) was
required for IL-22–mediated intracellular killing. Further studies
will be required to establish the functional relevance of this
pathway in an intact immune system and to establish the specific
interactions among S100A9, RAB7, and the phagolysome. Although
our data suggest that IECs may be less susceptible to S. enterica
Typhimurium colonization when the IL-22 pathway is functional,
in vivo Salmonella has been observed to cross the epithelial barrier
via M cells and direct capture from the lumen by phagocytes (31).
This might help explain why Il22−/−mice are not more susceptible to
S. enterica Typhimurium infection in vivo, although this lack of
susceptibility could also be attributable to depletion of the protective
microbiota by IL-22–mediated antimicrobials (20). Here, our data
showed differences after preincubation with IL-22 that might be
more relevant to later stages of infection. However, in several
models S. enterica Typhimurium has been shown to take longer than
expected to breach the intestinal epithelium (32), and IL-22 ex-
pression, along with genes induced by IL-22, are highly expressed
during the initial phases of infection (33, 34), suggesting that this
pathway may also have an impact on earlier interactions in vivo.
It would be tempting to speculate that the phenotype of infantile
severe colitis in IL10R2-deficient patients may be at least par-
tially attributable to reduced barrier function at the epithelial tis-
sues. In addition to their well-characterized defective response to
Fig. 5. IL-22–induced calgranulin B enhanced iHO colonization resistance to S. enterica Typhimurium infection. (A) Direct blocking of phagolysosomal fusion
with phagolysosomal inhibitors restricts IL-22–mediated protection in iHOs. Kolf2 iHOs were pretreated with 100 ng/mL IL-22 for 18 h and then were treated
with the phagolysosomal inhibitors W7 at 50 μM for 6 h or concanamycin A (CCMA) at 100 nM for 4 h or were left untreated, after which gentamicin
protection assays were performed. There was no significant difference in intracellular recovered bacteria from W7- or concanamycin A-treated iHOs and
untreated iHOs (W7, P = 0.7015; CCMA P = 0.0631, IL-22, ***P < 0.0001; unpaired, two-tailed Mann–Whitney U tests). Data presented show the mean from
four biological replicates with three technical replicates per assay, ± SEM. (B and C) RT-qPCR was performed with a TaqMan gene-expression assay specific for
RAB7A (B) or S100A9 (C) and was analyzed via the comparative CT method with GAPDH as an endogenous control. Data presented show the mean fold
change between untreated samples and infected samples from three biological replicates, ± SEM. There was a significant difference in RAB7A and S100A9
expression in iHOs pretreated with IL-22 in comparison with iHOs left untreated before infection (RAB7A: P = 0.0001; S100A9: P < 0.0001; unpaired, two-tailed
Student’s t tests). (D) Kolf2 iHOs challenged with IL-22 for 18 h or left untreated were microinjected with S. enterica Typhimurium SL1344 and examined for
RAB7 (red), CSA-1 (green), and DAPI (blue) by immunofluorescence with colocalization between RAB7 and CSA-1 (yellow) visible in IL-22–pretreated samples.
(Original magnification: 63×.) (E) Expression of S100A9 (green) by IL-22/S. enterica Typhimurium-treated Kolf2 and S100A9−/− iHOs was examined using
immunofluorescence. (F) Protection assays in S100A9−/− iHOs show that pretreatment with IL-22 results in no significant difference in recovered intracellular
bacterial after microinjection of S. enterica Typhimurium SL1344, in contrast to Kolf2 iHOs. (G) S100A9−/− or Kolf2 iHOs treated with IL-22 for 18 h and then
microinjected with S. enterica Typhimurium SL1344 were examined for RAB7 (red), CSA-1 (green), and DAPI (blue) by immunofluorescence; RAB7 was not
visible in S100A9−/− samples. (Original magnification: 40×.) n.s., not significant; ***P < 0.0001.
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the antiinflammatory cytokine IL-10 in immune cells (35), patients
with IL10RB defects might also exhibit reduced barrier function
(7). However, the clinical presentation in patients with loss of
function mutations in IL-10, IL10RA, and IL10RB is similarly se-
vere, and IL10RB mutations have not been associated with en-
hanced enteric infection, suggesting that this pathway in the
epithelium may be redundant in vivo. Further understanding of the
epithelial defects in patients with IL-10 signaling defects is be-
coming increasingly important, given that hematopoietic trans-
plantation is a curative therapeutic option in patients with IL-10/
IL10R deficiency (7, 36), and it will be important to investigate
whether there are differences in the posttransplant intestinal in-
fection susceptibility between patients with IL-10 and IL10RA
defects on the one side and patients with IL10RB defects on
the other.
Materials and Methods
Generation and Culture of hIPSCs and Directed Differentiation to iHOs. The
healthy control hIPSC lines Yemz1, Lise1, and Kolf2, were acquired through
the Human Induced Pluripotent Stem Cells Initiative Consortium (HipSci;
www.hipsci.org), through which they were also characterized (37). Consent
was obtained for the use of cell lines for the HIPSCI project from healthy
volunteers. A favorable ethical opinion was granted by the National Re-
search Ethics Service (NRES) Research Ethics Committee Yorkshire and The
Humber – Leeds West, reference number 15/YH/0391. IL10RBPat hIPSCs were
generated at the Wellcome Trust Sanger Institute (WTSI) as part of the
Oxford IBD cohort study/COLORS in IBD (Colitis of Early Onset—Rare Dis-
eases Within IBD Disease Phenotypes) project with appropriate ethical
approvals [REC: 09/H1204/30; North Staffs Local Research Ethics Committee/
NRES Committee West Midlands – The Black Country (IBD in Oxford)]. hIPSC
lines were differentiated into endoderm, hindgut, and then iHOs using a
previously published protocol (14, 38). For production of primary organoids,
mucosal tissue was harvested and seeded according to protocols described
by Sato and coworkers (39) and Fordham et al. (40). Control human intestinal
samples were collected from the ascending colon and ileum of children under
16 y of age undergoing routine diagnostic endoscopy, following ethical ap-
proval (REC-12/EE/0482; NRES Committee East of England–Hertfordshire) and
informed consent. All other methods are described in SI Appendix, SI Materials
and Methods.
Data Availability. The RNA-seq data have been deposited in the European
Nucleotide Archive (accession no. ERP024278).
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